购物车
- 全部删除
- 您的购物车当前为空
KAT681 is a liver selective thyromimetic.
KAT681 is a liver selective thyromimetic.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | |
50 mg | ¥ 13,800 | 6-8周 | |
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | KAT681 is a liver selective thyromimetic. |
体外活性 | Prolonged treatment with KAT681 enhances the hepatic expression of both low-density lipoprotein (LDL) receptor and scavenger receptor class B, type I without affecting cholesteryl ester transfer protein activity. SR-BI protein expression is markedly downregulated by incubation with 50 μg/mL AcLDL. This effect can not be reversed by the addition of KAT681. Western blot showing human SR-BI (CLA-1) expression in normal HepG2 cells and in HepG2 cells loaded with AcLDL and subsequently incubated with vehicle or KAT681 [1]. |
体内活性 | KAT681 treatment causes a 60% decrease in plasma cholesterol and a 70% decrease in plasma triglycerides[1]. KAT681 obviously enhances hepatic LDLrs in SR-BI KO mice (2-fold of controls, P<0.01), along with a marked decrease in plasma cholesterol[2]. A marked decrease of plasma cholesterol is observed at 36 nmoles/kg/day KAT681 (T-0681), whereas doses higher than 36 nmoles/kg/day display no further lipid-lowering effect, in preliminary dose-titration studies. A marked increase of hepatic SR-BI expression at 36 nmol/kg/d KAT681 (T-0681) and a concomitant 50% decrease of plasma cholesterol are observed, in preliminary dose-titration studies in wild-type (WT) mice. New Zealand White (NZW) rabbits are fed a 0.2% cholesterol diet and dosed with 36 nmoles/kg/day KAT681 or respective placebo control for 4 weeks, in the subsequent study. Higher doses than 36 nmol/kg/d display no further lipid-lowering effect. |
别名 | T0681 |
分子量 | 462.429 |
分子式 | C24H22FNNaO6 |
CAS No. | 373641-87-3 |
密度 | 1.31g/cm3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容